Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hygeia Pharmaceuticals
Shanghai, Shanghai, Chinaen.hygieiapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Initial clinical results for programs such as Hepa Thera (chronic HBV) and Kylo-11 (hyperlipidemia) show "good safety, tolerability, BIC therapeutic potential" in Phase 1; stronger efficacy at lower dose vs late-stage competitors.
- Therapeutic areas
- ImmunologyMetabolic DisordersInfectious DiseasesCardiovascularNeurology
- Modalities
- Small interfering RNARNA therapy
- Industry
- Biotech
02
Partnerships
Open to global collaborations for assets and platform access
Beyond the preview
Go deeper on Hygeia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hygeia Pharmaceuticals.